Medicinal Chemistry in the era of Big Data

A few days ago I read an article written by Scott J. Lusher, with whom we collaborated at Intelligent Pharma some years ago. The article is entitled “Data-driven medicinal chemistry in the era of big data” and it has been published in Drug Discovery Today.

The author says that modern research is characterised by four points:
i. The access to, and requirement to, manage large amounts of data.
ii. The requirement for all researchers to become data scientists.
iii. The increased complexity of research projects.
iv. The need to work effectively in larger teams with colleagues from multiple disciplines and multiple locations.
Read More

28/10/2014 | Tags:
Drug discovery
,  Medicinal Chemistry
,  Research
,  Computational Chemistry
Share on facebook
Share on twitter
Share on email
Share on print
More Sharing Services

4 comments.
Chemical Biology and Computational Chemistry

Currently, a hot research area in drug discovery is Chemical Biology. Generally speaking, Chemical Biology uses synthetically generated molecules to study a biological system. In some sense, Chemical Biology has been around since many years, even though sometimes unrecognized. For example, since quite a long time fluorophores have been used as probes to study mechanisms in the cell. Similarly, many other experimental methods traditionally used in Biochemistry, Molecular Biology or Synthetic Chemistry and, therefore, also related analytical detection systems may be applied in Chemical Biology. Summarizing, the knowhow of experts from different fields can be used to create a Chemical Biology department. This has allowed big companies to hop on the Chemical Biology train in a fast way by somehow restructuring their scientific departments. Nowadays, all the big players work in the field, including Astra Zeneca, Pfizer, Novartis and Genentech. Also new biotechs like Forma Therapeutics or h3biomedicine are still created on principals of Chemical Biology.
Read More

29/07/2014 | Tags:
Drug discovery
,  Medicinal Chemistry
,  Research
,  Computational Chemistry
Share on facebook
Share on twitter
Share on email
Share on print
More Sharing Services

1 comments.
Promising new drug targets with high risk
Intrinsically Disordered Proteins (IDPs) are promising drug targets as they are involved in many biological processes. Still, industry invests little money in the discovery and development of drugs which interfere with IDPs. Recent failures as in the case of the development of Alzheimer drugs, which try to stop the formation of protein aggregates, do not help to move this high potential field forward. IDPs are still considered high risk targets; a perfect area for universities to create value but also the right investment for high risk, high profile biotech start-ups.

Read More

05/06/2014 | Tags:
Drug discovery
,  Medicinal Chemistry
,  Research
,  Computational Chemistry
Share on facebook
Share on twitter
Share on email
Share on print
More Sharing Services

No comments yet!
On Virtual Pharmaceutical Companies
Virtual Pharmaceutical Companies (VPC) are a type of companies that differ from other R&D companies, such as biotech start-ups, because they solely comprise experienced teams of managers and consultants which coordinate and monitor on a contractual basis a set of service providers to perform all operational activities to develop one or several drug candidates. Virtualization of companies, especially in the pharmaceutical field, is a management trend that started to emerge five years ago and now is completely usual. In fact, amongst Intelligent Pharma’s clients, there are multiple VPC’s.
Read More

30/04/2014 | Tags:
Drug Discovery
,  Management
,  Research
Share on facebook
Share on twitter
Share on email
Share on print
More Sharing Services

8 comments.